Ocugen Inc
Change company Symbol lookup
Select an option...
OCGN Ocugen Inc
INST Instructure Holdings Inc
TOMZ TOMI Environmental Solutions Inc
TNL Travel + Leisure Co
PSAGW Property Solutions Acquisition Corp II *W EXP 03/01/2026
AMZN Amazon.com Inc
GSK GlaxoSmithKline PLC
TSLA Tesla Inc
MMD MainStay MacKay DefinedTerm Municipal Opportunities Fund
APSG Apollo Strategic Growth Capital
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Ocugen, Inc. is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing vaccine for COVID-19. The Company's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. COVID-19 Vaccine is developing, manufacturing and commercializing COVAXIN for the prevention of COVID-19 in humans in the Ocugen Covaxin Territory. COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus. The Modifier Gene Therapy platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). It is developing OCU200, a novel biologic product candidate to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet AMD. OCU400, its first product candidate being developed with its modifier gene therapy platform.

Price
Delayed
$8.76
Day's Change
-1.29 (-12.80%)
Bid
--
Ask
--
B/A Size
--
Day's High
10.07
Day's Low
8.56
Volume
(Heavy Day)

Today's volume of 36,854,531 shares is on pace to be much greater than OCGN's 10-day average volume of 31,046,379 shares.

36,854,531

Company Profile

Ocugen, Inc. is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing vaccine for COVID-19. The Company's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. COVID-19 Vaccine is developing, manufacturing and commercializing COVAXIN for the prevention of COVID-19 in humans in the Ocugen Covaxin Territory. COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus. The Modifier Gene Therapy platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). It is developing OCU200, a novel biologic product candidate to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet AMD. OCU400, its first product candidate being developed with its modifier gene therapy platform.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
15.75x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

September 2021
Current Month
53.1M
Previous Month
52.8M
Percent of Float
27.37%
Days to Cover
5.3817 Days

Share Information

OCGN is in a share class of common stock
Float
193.9M
Shares Outstanding
198.8M
Institutions Holding Shares
164
27.14%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Shankar MusunuriChmn.
  • Sanjay SubramanianCFO
  • Vijay TammaraSr.VP
  • Kirsten Castillo
  • Prabhavathi B. Fernandes

Address

Insider Trading

During the most recent quarter, 1M shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.